Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems (NYSE: VEEV) announced that Indero, formerly Innovaderm Research, has successfully completed its 40th study implementation using Veeva RTSM (Randomization and Trial Supply Management). This milestone demonstrates the successful standardization of Indero's clinical trial operations using Veeva's RTSM platform.
The specialized CRO has leveraged Veeva RTSM's advanced capabilities to enhance operational efficiency, improve process consistency, and streamline trial execution. Eric Hardy, senior director of biometrics at Indero, highlighted that the platform has enabled more efficient processes and better collaboration, ultimately accelerating the path to bringing therapies to market.
The partnership between Indero and Veeva has focused on developing and implementing standardized processes for long-term clinical trial success, with Veeva's enterprise standard RTSM approach contributing to greater efficiency and reliability in study execution.
Veeva Systems (NYSE: VEEV) and Boehringer Ingelheim have successfully launched the 'One Medicine Platform' powered by Veeva Development Cloud, marking a significant milestone in their collaboration announced in March 2022. The platform unifies data and processes across clinical, regulatory, and quality functions.
As one of the top 20 biopharma companies, Boehringer Ingelheim is leveraging this unified platform to streamline product development, optimize trial efficiency, and enhance collaboration with research sites. The implementation enables seamless data connectivity across functions, aiming to accelerate the delivery of new treatments for currently incurable diseases.
The Veeva Development Cloud serves as the technology foundation, integrating clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Veeva Systems (NYSE: VEEV) reported strong financial results for Q4 and fiscal year 2025. Total revenues reached $2,746.6M for FY2025, up 16% YoY, with Q4 revenues at $720.9M, up 14% YoY. Subscription services revenues grew 20% YoY to $2,284.7M for FY2025.
The company demonstrated significant profitability improvements with FY2025 operating income increasing 61% YoY to $691.4M. Net income rose 36% YoY to $714.1M, with diluted EPS of $4.32.
Veeva expanded its customer base to 1,477 total customers, with 1,125 in R&D Solutions and 730 in Commercial Solutions. The company's Vault CRM Suite saw notable adoption with over 50 customers live. Looking ahead, Veeva projects Q1 FY2026 revenues between $726-729M and FY2026 total revenues of $3,040-3,055M.
Veeva Systems (NYSE: VEEV) has launched Veeva CRM Pulse, a quarterly data subscription service providing HCP access and multichannel engagement metrics for the life sciences industry. The service leverages data from over 500 million Veeva CRM interactions, covering more than 3 million healthcare professionals across 102 specialties in 21 countries.
CRM Pulse offers brick-level HCP access data for segmentation, targeting, and engagement planning, featuring true industry census data based on Veeva's CRM Suite usage. The service is currently available to Veeva's CRM customers with 2024 quarterly data covering major markets including the US, Canada, and various European and Asian countries. Quarterly data releases for 2025 will commence in April, with plans to expand coverage to additional Asian and European countries next year.
Veeva Systems (NYSE: VEEV) has launched Veeva Commercial Pulse, a quarterly data subscription service providing HCP access and multichannel engagement metrics for the life sciences industry. The service leverages data from over 500 million Veeva CRM interactions to deliver insights across 21 countries.
Commercial Pulse offers comprehensive coverage of more than 3 million healthcare professionals across 102 specialties, with metrics segmented by country, specialty, and brick for data privacy. The service is currently available with 2024 quarterly data for major markets including the US, Canada, and various European and Asian countries, with 2025 quarterly releases beginning in April.
The solution is part of Veeva Data Cloud, alongside Veeva OpenData, Link, and Compass, aimed at improving segmentation and targeting for commercial operations and data analytics teams.
Veeva Systems (NYSE: VEEV) has announced that 6 of the top 20 biopharmas have selected Veeva China CRM Suite for healthcare professional (HCP) engagement in China. The suite is specifically developed in China for China, while adhering to Veeva's global development standards for compliance and quality.
The China-specific solution includes local requirements and technologies, in-country hosting, and compliance with privacy and data export regulations. The suite comprises several applications including China CRM, China Events Management, Approved WeChat, China Engage, and China Campaign Manager.
As part of Veeva Commercial Cloud, the global technology foundation for commercial excellence, the suite integrates seamlessly with other Veeva products such as PromoMats, Network, and OpenData.
Veeva Systems (NYSE: VEEV) announced the inclusion of Direct Data API with Veeva Vault Platform at no additional license fee. This new API enables data access up to 100 times faster than traditional APIs and ensures transactional integrity across large datasets.
The Direct Data API will feature connectors for Amazon Redshift, Snowflake, Databricks, and Power BI later this year. This technology advancement is part of Veeva's strategy to enable advanced automation and AI in life sciences, supporting developments like TMF Bot, Vault CRM Bot, and Vault CRM Voice Control.
The API allows customers and partners to efficiently extract full or incremental Vault data, facilitating AI applications, analytics, and system-to-system integrations.
Veeva Systems (NYSE: VEEV) has announced it will release its financial results for the fourth quarter and full fiscal year 2025, which ended January 31, 2025, after market close on March 5, 2025. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results.
Prepared remarks will be posted to Veeva's investor relations website approximately one hour before the call. A webcast replay will be available following the live event.
Veeva Systems (NYSE: VEEV) announced that over 200 companies, including 17 of the top 20 biopharmas, are now using Veeva CTMS for clinical trial management. The platform helps streamline trial processes and enhance collaboration as studies become more complex and data-intensive.
The system serves as a central hub for managing study metrics and documents, enabling both insourced and outsourced trial operations while maintaining compliance with global regulations like ICH E6(R2) and (R3). New features include automated CRO-to-sponsor data transfers, improved oversight issue tracking, and enhanced capabilities for managing complex trials.
Veeva CTMS is part of the broader Veeva Clinical Platform, designed to accelerate trial execution and improve operational efficiency. The company continues to enhance the platform through three product releases annually.
Veeva Systems (NYSE: VEEV) and Zifo announced a product partnership aimed at modernizing quality control operations in biopharma. The integration combines Veeva LIMS with Zifo's data integration platform, qcKen, enabling direct data import from any source document or other LIMS systems.
The partnership will simplify master data configuration during LIMS implementation and site deployment, helping companies transition from legacy QC systems. The collaboration focuses on streamlining test and specification data creation, expediting implementation processes, and delivering faster ROI for new Veeva LIMS customers.
As part of the agreement, Zifo becomes an official Veeva Product Partner, expanding their existing relationship as a Veeva Services Partner. The integration aims to support GMP quality business processes with greater accuracy while helping organizations increase scale and speed batch release cycles.